Aurora
kinase are proteins that function as mitotic regulators and are
aberrantly expressed in cancerous cells. Aurora kinase inhibitors target these
aberrantly expressed regulators, provides genetic stability and prevents
tumorigenesis.
Several studies have demonstrated overexpression and
amplification of aurora kinase in various haematological and solid cancers.
Aurora kinase inhibitors when combined with other anti-cancer agents gives more
positive results in variety of cancers. Better evaluation of aurora kinase
inhibitors is required which raises the need of biomarkers, effective and novel
therapeutic agents. Also, aurora kinase inhibitors selectivity targets cancer
cells rather than healthy tissues, providing potential opportunities for more
effective drug development with reduced adverse effects.
Request to Get the Sample Pages at:
AstraZeneca PLC is in the process of developing AZD-2811 as
a small molecule which acts as an aurora B inhibitor for the treatment of solid
tumors. Some of the other companies having pipeline of aurora kinase inhibitors
include AbbVie Inc., Merck & Co., Inc., and CASI Pharmaceuticals Inc.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with detailed analysis of pipeline and clinical trials. Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licencing, grants, technology and others.
